Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC22A2 | O15244 | 17/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.46 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23026383 | 1.00 | SLC22A2 (0.51) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL21696359 | 0.93 | SLC22A2 (0.51) | SLC22A2 | |
| SCHEMBL81225 | 0.89 | SLC22A2 (0.51) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL23026388 | 0.88 | SLC22A2 (0.49) | SLC22A2 | |
| SCHEMBL21696408 | 0.87 | SLC22A2 (0.50) | SLC22A2 | |
| SCHEMBL23026361 | 0.87 | SLC22A2 (0.50) | SLC22A2 | |
| SCHEMBL83470 | 0.86 | SLC22A2 (0.52) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL23026372 | 0.85 | SLC22A2 (0.55) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL21696407 | 0.85 | SLC22A2 (0.55) | SLC22A2CYP3A4TMEM97ABCG2 | |
| SCHEMBL21696376 | 0.85 | SLC22A2 (0.64) | SLC22A2CYP3A4TMEM97ABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4122935-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| EP-3608325-A1 | POLYCYCLIC-CARBAMOYLPYRIDONE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Gilead Sciences, Inc. (US) | 2020-02-12 | — | — | EP | disclosed |